Restoring Resilience in the Face of Chronic Disease: A Differentiated Approach to Fibrosis Drug Development
9:00 am - Thursday 3rd December 2026
- Exploring why and how chronic disease drug development should look beyond what goes wrong in disease and instead leverage the protective biology that enables younger, healthier tissues to cope with disease-associated stressors
- Demonstrating how FOXO3 activation modulates fibroblast and epithelial-cell transdifferentiation across fibrotic environments, providing a broader approach than targeting a single disease-driving pathway
- Building an integrated evidence package by utilizing a variety of models, including tissue slice models, to demonstrate the potential of Refoxy’s lead program
